Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer
- Registration Number
- NCT05670457
- Lead Sponsor
- Tanta University
- Brief Summary
The aim of the study is to evaluate the safety and efficacy of diosmin as adjuvant therapy in treatment of non-bleeding peptic ulcer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
-. Age 25-65 years old.
- Patients of both gender (male and female).
- Non-bleeding Peptic ulcer Patients (duodenal &gastric) diagnosed by endoscopy.
Exclusion Criteria
-
The presence of other factors that can lead to gastric bleeding other than peptic ulcer.
- Patients with cancerous disease
- Breast-feeding.
- Surgically altered stomach ( bariatric surgery),
- Patient with liver disease.
-
Bleeding & perforated peptic ulcer.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Diosmin group Diosmin this group will include 22 patients who will receive anti peptic ulcer and diosmin 500 mg twice daily for 2 months.
- Primary Outcome Measures
Name Time Method assesment of improvement of symptoms as indicated by change in SAGIS scale. 2 months patients will undergo clinical assessment according to SAGIS scale at baseline and 2 months
- Secondary Outcome Measures
Name Time Method change in Malondialdehyde (MDA) serum levels. 2 months blood samples will be collected at baseline and 2 months.
change in Prostaglandin E2 (PGE2) serum levels. 2 months. blood samples will be collected at baseline and 2 months.
change in Endothelin-1 (ET-1) serum levels. 2 months blood samples will be collected at baseline and 2 months.
change in b-cell lymphoma 2(bcl-2) serum levels. 2 months blood samples will be collected at baseline and 2 months.
Trial Locations
- Locations (1)
Tanta University
🇪🇬Tanta, El Gharbia, Egypt